5-Hydroxtryptamine Receptors in Systemic Hypertension: An Arterial Focus

Cardiovascular Therapeutics

Volumn 29, Issue 1, 2011, Pages 54-67

  Watts, Stephanie W ^a   Davis, Robert Patrick ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Hypertension; Pharmacodynamics; Serotonin; Vascular biology

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 3 (3 DIMETHYLAMINOPROPYL) 4 HYDROXY N [4 (4 PYRIDINYL)PHENYL]BENZAMIDE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; ALNIDITAN; BRL 54443; CP 930129; ELETRIPTAN; ISAMOLTANE; L 703664; LY 344370; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; PHENYLBIGUANIDE; SB 236057; SB 272183; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SUMATRIPTAN; U 92016 A; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZACOPRIDE;

ALLOSTERISM; ARTERY; BINDING AFFINITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; DRUG RECEPTOR BINDING; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR RESISTANCE;

ARTERIES; BLOOD PRESSURE; HUMANS; HYPERTENSION; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 78751560362     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00173.x     Document Type: Review

References (150)

1. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol 1957;12:323-328.
2. Hoyer D, Martin GR, Andrade R, et al. 5-HT Receptors. Available from: [Assessed 29 October 2009.
3. 3 receptors. Available from: [Accessed 17 April 2010.
4. Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin) IV. Isolation and characterization. J Biol Chem 1948;176:1243-1251.
5. Page IH, McCubbin JW. The variable arterial response to serotonin in laboratory animals and man. Circ Res 1953a;1:354-362.
6. Page IH, McCubbin JW. Modification of vascular responses to serotonin by drugs. Am J Physiol 1953b;174:436-440.
7. Erspamer V, Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 1952:169;800-801.
8. Harington C. Opening Remarks. In: Lewis GP, editor. 5-Hydroxytryptamine. London: Pergamon Press, 1958;2.
9. Azmitia EC. Modern views on an ancient chemical: Serotonin effects on cell proliferation, maturation and apoptosis. Brain Res Bull 2001;56:413-424.
10. Kuhn DM. Tryptophan hydroxylase regulation. Drug-induced modifications that alter serotonin neuronal function. Adv Exp Med Biol 1999;467:19-27.
11. Walther DJ, Bader MA. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003;66:1673-1680.
12. Walther DJ, Peter J-U, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second trytophan hydroxylase isoform. Science 2003;299:76.
13. Stahl SM, Felker A. Monoamine oxidase inhibitors: A modern guide to an unrequited class of antidepressants. CNS Spectr 2008;13:855-870.
14. Wakayama K, Ohtsuki S, Takanaga H, Hosoya K, Terasaki T. Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells. Neursci Res 2002;44:173-180.
15. Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H. Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci 2008;27:2466-2472.
16. Weir EK, Hong Z, Varghese A. The serotonin transporter: A vehicle to elucidate pulmonary hypertension? Circ Res 2004;94:1152-1154.
17. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: A platelet connection. Cell Mol Life Sci 2005;62:159-170.
18. Ni W, Geddes TJ, Priestley JR, Szasz T, Kuhn DM, Watts SW. The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol 2008;154:663-674.
19. Linder AE, Ni W, Szasz T, et al. A serotonergic system in veins: Serotonin-transporter independent uptake. J Pharmacol Exp Ther 2008;325:714-722.
20. Doggrell SA. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin Investig Drugs 2003;12:805-823.
21. Cote F, Fligney C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 2004;10:232-238.
22. Nebigil CG, Maroteaux L. A novel role for serotonin in heart. Trends Cardiovasc Med 2001;11:329-335.
23. Marwood JF, Stokes GS. Serotonin (5-HT) and its antagonists: Involvement in the cardiovascular system. Clin Exp Pharmacol Physiol 1984;11:439-456.
24. Vanhoutte PM. Serotonin, hypertension and vascular disease. Neth J Med 1991;38:35-42.
25. Ramage AG, Villalon CM. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 2008;29:472-481.
26. Côté F, Fligny C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 2004;10:232-238.
27. Kaumann AJ, Levy FO. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006;111:674-706.
28. Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytryptamine: A pharmacological update on receptors/mechanisms involved and therapeutic implications. Naunyn-Schmiedeberg's Arch Pharmacol 2007;376:45-63.
29. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71:533-554.
30. 1 receptors with other receptors: Clinical implications. Neuropharmacology 2008;55:986-993.
31. Kenakin T. Collateral efficacy in drug discovery: Taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 2007;28:407-415.
32. Violin JD, Lefkowitz RJ. β-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007;28:416-422.
33. 2C receptors. Pharmacol Ther 2009;121:160-173.
34. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320:1-13.
35. 1A receptors. Neuropharmacology 2001;40:334-344.
36. Newman-Tancredi A, Conte C, Chaput C, Spedding M, Millan MJ. Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist WAY100, 635. Br J Pharmacol 1997;120:737-739.
37. Cosi C, Koek W. The putative <> 5-HT1A receptor antagonist WAY100635, has inverse agonist preoperties at cloned human 5-HT1A receptors. Eur J Pharmacol 2000;401:9-15.
38. Audinot V, Newman-Tancredi A, Cussac D, Millan MJ. Inverse agonist properties of antipsychotic agents at cloned human (h) serotonin (5-HT) (1B) and h5-HT (1D) receptors. Neuropsychopharmacol 2001;25:410-422.
39. Audinot V, Newman-Tancredi A, Millan MJ. Constitutive activity at serotonin 5-HT(1D) receptors: Detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms. Neuropharmacology 2001;40:57-64.
40. 1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea pig. Naunyn Schmiedeberg Arch Pharmacol 2000;362:177-183.
41. 2A receptor inverse agonist. J Pharmacol Exp Ther 2010;332:622-631.
42. 2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther 2010;332:281-290.
43. Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T. Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: Comparison with those of sarpogrelate. J Pharmacol Sci 2009;110:445-450.
44. 2B receptor inverse agonist/antagonist activity. Eur J Pharmacol 2009;615:1-9.
45. 2C receptors: Differential modulation of cell surface expression and signal transduction. Mol Pharmacol 2008;73:748-757.
46. 2C receptors after chronic treatment. Psychopharmacol 2001;157:180-187.
47. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine (2C) receptor. J Pharmacol Exp Ther 2001;299:83-89.
48. 2C receptors. J Pharmacol Exp Ther 2000;295:226-232.
49. 2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 1994;269:11, 687-11, 690.
50. Claeysen S, Sebben M, Becamel C, Eglen RM, Clark RD, Bockaert J, Dumuis A. Pharmacological properties of 5-hydroxytryptamine(4) receptor antagonists on constitutively active wild-type and mutated receptors. Mol Pharmacol 2000;58:136-144.
51. 7 serotonin receptors: Inverse agonist activity of antipsychotic drugs. Psychopharmacology 2005;179:461-469.
52. 7a receptors coupled to adenylyl cyclase: Detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol 2007:376:93-105.
53. 7a receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonist. Naunyn Schmiedebergs Arch Pharmacol 2006;374:31-39.
54. 7 serotonin receptor. Eur J Pharmacol 2006;532:1-10.
55. Watts SW. 5-HT in systemic hypertension: Foe, friend or fantasy? Clin Sci 2005;108:399-412.
56. Dalton DW, Feniuk W, Humphrey PP. An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and DOCA-salt hypertensive rats. J Auton Pharmacol 1996;6:219-228.
57. Chapman ME, Wideman RF. Hemodynamic responses of broiler pulmonary vasculature to intravenously infused serotonin. Poult Sci 2002;81:231-238.
58. Linden A, Desmecht D, Amory H, Lekeux P. Cardiovascular response to intravenous administration of 5-hydroxytryptamine after type-2 receptor blockade, by metrenperone, in healthy calves. Vet J 1999;157:31-37.
59. Nelson M, Coghlan JP, Denton DA, Tresham JJ, Whitworth JA, Scoggins BA. Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep. Clin Exp Pharmacol Physiol 1987;14:555-563.
60. Thompson LP, Webb RC. Vascular responsiveness to serotonin metabolites in mineralocorticoid hypertension. Hypertension 1987;9:277-281.
61. McGregor DD, Smirk FH. Vascular responses to 5-hydroxytryptamine in genetic and renal hypertensive rats. Am J Physiol 1970;219:687-690.
62. Nishimura Y. Characterization of 5-hydroxytryptamine receptors mediating contraction in basilar arteries from stroke-prone spontaneously hypertensive rats. Br J Pharmacol 1996;117:1325-1333.
63. Dohi Y, Luscher TF. Altered intra- and extraluminal effects of 5-hydroxytryptamine in hypertensive mesenteric resistance arteries: Contribution of the endothelium and smooth muscle. J Cardiovasc Pharmacol 1991;18:278-284.
64. Akbar H, Chen NY, Fossen DV, Wallace W. Increased vascular contractile sensitivity to serotonin in spontaneously hypertensive rats is linked with increased turnover of phosphoinositide. Life Sci 1989;45:577-583.
65. Nishimura Y, Suzuki A. Enhanced contractile responses mediated by different 5-HT receptor subtypes in basilar arteries, superior mesenteric arteries and thoracic aortas from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995;1:S99-S101.
66. Boston PC, Hodgson WC. Changes in reactivity towards 5-hydroxytryptamine in the renal vasculature of the diabetic spontaneously hypertensive rat. J Hypertens 1997;15:769-774.
67. Roson MI, Maquieira MK, de la Riva IJ. Contrasting effects of norepinephrine and 5-hydroxytryptamine on contractility of abdominal aorta of two kidney-two clip hypertensive rats. Effects of inhibitors of arachidonic acid metabolic enzymes. Clin Exper Hyper Theory and Practice A 1990;12:285-306.
68. Morelowska-Spierzak D, Pawlak D, Buczko W. Influence of captopril on the serotonin-induced vasopressor effect in tail artery isolated from two-kidney, one-clip renal hypertensive rats. Pol J Pharmacol 1995;47:417-422.
69. Moreno L, Martinez-Cuesta MA, Pique JM, Bosch J, Esplugues V. Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 1996;354:474-480.
70. Cummings SA, Groszmann RJ, Kaumann AJ. Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 1986;89:501-513.
71. 2B receptor mediates contraction in the mesenteric artery of mineralocorticoid hypertensive rats. Hypertension 1995;26:1056-1059.
72. 2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther 1996;277:1103-1113.
73. Hutri-Kahonen N, Kahonen M, Wu X, Sand J, Nordback I, Taurio J, Porsti I. Control of vascular tone in isolated mesenteric arterial segments from hypertensive patients. Br J Pharmacol 1999;127:1735-1743.
74. Yildiz O, Cicek S, Ay I, Demirkilic U, Tuncer M. Hypertension increases the contractions to sumatriptan in the human internal mammary artery. Ann Thorac Surg 1996;62:1392-1396.
75. Webb RC, Schreur KD, Papadopoulos SM. Oscillatory contractions in vertebral arteries from hypertensive subjects. Clin Physiol 1992;12:69-77.
76. Wyse DG. Relationship of blood pressure to the responsiveness of an isolated human artery to selected agonists and to electrical stimulation. J Cardiovasc Pharmacol 1984;6:1083-1091.
77. 2B receptor antagonist LY272015 inhibits 5-HT-induced contraction in the aorta of mineralocorticoid-salt hypertensive rats. J Ser Res 1997;4:197-206.
78. 1B receptors during development of DOCA-salt hypertension. BMC Pharmacology 2003;3:12.
79. 2B receptors in DOCA-salt hypertension. Hypertension 2002;39:394-398.
80. 2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol 1995;114:400-404.
81. Glusa E, Roos A. Endothelial 5-HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine. Br J Pharmacol 1996;119:3303-3304.
82. 7 receptor-mediated relaxation in pulmonary arteries of weaned pigs. Naunyn-Schmied Arch Pharmacol 2005;371:89-98.
83. 2B, receptors mediate hypotension in vagosympathetctomized rats. Eur J Pharmacol 2004;502:239-242.
84. 7 receptor mediated depressor responses in rats. Naunyn-Schmied Arch Pharmacol 1999;359:331-338.
85. Terrón JA. Role of 5-ht7 receptors in the long-lasting hypotensive response induced by 5-hydroxytryptamine in the rat. Br J Pharmacol 1997;121:563-571.
86. Villalon CM, Terron JA, Hong E. Role of 5-HT1 like receptors in the increase in external carotid blood flow induced by 5-hydroxytryptamine in the dog. Eur J Pharmacol 1993;240:9-20.
87. 1B/1D receptors mediate hypotension in anesthetized rats. Eur J Pharmacol 2007;576:132-135.
88. Gothert M, Molderings GJ, Fink K, Schlicker E. Heterogeneity of presynaptic serotonin receptors on sympathetic neurons in blood vessels. Blood Vessels 1991;28:11-18.
89. 1D subtype. Naunyn Schmiedebergs Arch Pharmacol 1990;342:371-377.
90. Shepherd JT, Vanhoutte PM. Local modulation of adrenergic neurotransmission in blood vessels. J Cardiovasc Pharmacol 1985;7(Suppl 3):S167-S178.
91. Kubo T, Su C. Effect of serotonin and some other neurohumoral agents on adrenergic neurotransmission in spontaneously hypertensive rat vasculature. Clin Exp Hypertens A 1983;5:1501-1510.
92. Carrasco G, Cruz MA, Gallardo V, Miguel P, Lagos M, Gonzalez C. Plasma and platelet concentration and platelet uptake of serotonin in normotensive and pre-eclamptic pregnancies. Life Sci 1998;62:1323-1332.
93. Fetkovska N, Pletscher A, Ferracin F, Amstein , Buhler FR. Impaired uptake of 5-hydroxytryptamine in platelet in essential hypertension: Clinical relevance. Cardiovasc Drugs Ther 1990;4(Suppl 1):105-109.
94. Breuer J, Georgaraki A, Sieverding L, Baden W, Apitz J. Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 1996;17:214-219.
95. Fetkovska N, Amstein R, Ferracin F, Regenass M, Buhler FR, Pletscher A. 5-hydroxytryptamine kinetics and activation of blood platelets in patients with essential hypertension. Hypertension 1990;15:267-273.
96. 3H serotonin and endogenous content of serotonin in blood platelets in hypertensive patients. Hypertension 1984;6:568-574.
97. Reis F, Tavares P, Ribeiro CAF, Antunes F, Teixeira F. The peripheral serotonergic system and platelet aggregation in cyclosporine A-induced hypertensive rats. Thrombosis Res 1999;96:365-372.
98. Sang K-HLQ, Monetnay-Garestier T, Devynck M-A. Alterations of platelet membrane microviscosity in essential hypertension. Clin Sci 1991;80:205-211.
99. Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, Kilic F. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 2007;102:206-215.
100. Martin GF. Vascular receptors for 5-hydroxytryptamine: Distribution, function and classification. Pharmac Ther 1994;62:283-324.
101. Guo-Shu L, Da-Xian H, Xing-sheng Y, et al. Ketanserin in the treatment of hypertension: A multicentre dose-finding study in China. Clin Exper Hyper 1991;A13:541-555.
102. Vanhoutte P, Amery A, Birkenhager W, et al. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 1988;11:111-133.
103. van Zwieten PA, Blauw GF, van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol 1992;70:s17-s22.
104. Frishman WH, Okin S, Hubrfeld S. Serotonin antagonism in the treatment of systemic hypertension. Cardiovasc Pharmacother 1988;72:501-522.
105. Cohen ML, Fuller RW, Kurz KD. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats. Hypertension 1983;5:676-681.
106. Persson B, Gradin K, Pettersson A, Hedner T. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 1988;11(Suppl 1):S22-S24.
107. 2 receptor antagonist. Br Med J 1982;284:537-539.
108. van Schie DL, de Jeu RM, Steyn DW, Odendaal HJ, van Geijn HP. The optimal dosage of ketanserin for patients with severe hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol 2002;102:161-166.
109. 2 receptor antagonists ketanserin and LY53857 on blood pressure in anesethetized spontaneously hypertensive rats. J Pharmacol Exp Ther 1989;248:736-740.
110. Cohen ML, Fuller RW, Kurz KD. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther 1983;227:327-332.
111. 2 antagonist ritanserin on blood pressure and serotonin-induced platetlet aggregation in patients with untreated essential hypertension. Eur J Clin Pharmacol 1988;35:123-129.
112. 2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat. J Neural Transm 1985;64:145-149.
113. PDSP Ki Database. Available from: [Accessed 17 April 2010.
114. Althaus JS, Beckman JJ, Miller ED. Central serotonin depletion: Effect on blood pressure during anesthesia. Anesth Analg 1985;64:1163-1170.
115. Ding XR, Stier CT, Itskovitz HD. Serotonin and 5-hydroxytryptophan on blood pressure and renal blood flow in anesthetized rats. Am J Med Sci 1989;297:290-293.
116. Itskovitz HD, Werber JL, Sheridan AM, Brewer TF, Stier CT. 5-hydroxytrptophan and carbidopa in spontaneously hypertensive rats. J Hypertens 1989;7:311-315.
117. Baron A, Riesselmann A, Fregly MJ. Reduction in the elevated blood pressure of Dahl Salt sensitive rats treated chronically with L-5-hydroxytryptophan. Pharmacology 1991;42:15-22.
118. Echizen H, Freed CR. Long-term infusion of L-5-hydroxytryptophan increases brain serotonin turnover and decreases blood pressure in normotensive rats. J Pharmacol Exp Ther 1981;220:579-584.
119. Fregly MJ, Lockley OE, Sumners C. Chronic treatment with L-5-hydroxytryptophan prevents the development of DOCA-salt induced hypertension in rats. J Hypertens 1987;5:621-628.
120. Diaz J, Ni W, King A, Fink GD, Watts SW. 5-hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats. J Pharmacol Exp Ther 2008;325:1031-1038.
121. Kawasaki H, Takasaki K. Vasoconstrictor response induced by 5-hydroxytryptamine released from vascular adrenergic nerves by periarterial nerve stimulation. J Pharmacol Exp Ther 1984;229:816-822.
122. MacLennan SJ, Bolofo ML, Martin GR. Amplifying interactions between spasmogens in vascular smooth muscle. Biochem Soc Trans 1993;21:1145-1150.
123. Yildiz O, Smith JR, Purdy RE. Serotonin and vasoconstrictor synergism. Life Sci 1998;62:1723-1732.
124. 2B receptor antagonist LY272015 is antihypertensive in severely hypertensive deoxycorticosterone acetate salt rats. Am J Physiol Heart Circ 1999;276:H944-H952.
125. w-nitro-L-arginine hypertensive rat. J Pharmacol Exp Ther 2002;303:179-187.
126. Filshie GM, Maynard P, Hutter C, Cooper JC, Robinson G, Rubin P. Urinary 5-hydroxyindole acetate concentration in pregnancy induced hypertension. Br Med J 1992;304:1223.
127. Jelen I, Fananapazir L, Brawford TBB. The possible relation between late pregnancy hypertension and 5-hydroxytryptamine levels in maternal blood. Br J Obstetric Gynecol 1979;86:468-471.
128. Lin B, Zhu S, Shao B. Changes of plasma levels of monoamines in normal pregnancy and pregnancy-induced hypertension in women and their significance. Chung-Hua-Fu-chan-Ko-Tsa-Chih 1996;31:670-672.
129. Fujrati VR, Goyal A, Gaur SP, Singh N, Shanker K, Chandravati K. Relevance of platelet serotonergic mechanisms in pregnancy induced hypertension. Life Sci 1994;55:327-335.
130. Krygicz D, Azzadin A, Pawlak R, Malyszko JS, Pawlak D, Mysliwiec M, Buczko W. Cyclosporine a affects serotonergic mechanisms in uremic rats. Pol J Pharmacol 1996;48:351-354.
131. Azzadi A, Mysliwiec M, Wollny T, Mysliwie M, Buczko W. Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats. Thromb Res 1995;77:217-224.
132. Ding YA, Choud TC, Huan R. Are platelet cytosolic free calcium, serotonin concentration and blood viscosity different between hypertensive and normotensive subjects? Cardiology 1995;85:177-178.
133. Ni W, Thompson J, Northcott C, Lookingland K, Watts SW. The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 2004;43:770-781.
134. Lazartigues E, Brefel-Courbon C, Bagheri H, et al. Fluoxetine-induced pressor response in freely moving rats: A role for vasopressin and sympathetic tone. Fundam Clin Pharmacol 2000;14:443-451.
135. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Beasley C. (1999) Blood pressure changes during short term fluoxetine. J Clin Psychopharmacol 1999;19:9-14.
136. Tsai ML, Lin MT. Hypertension and tachycardia produced by inhibition of reuptake of 5-hydroxytryptamine by fluoxetine in the rat. Neuropharmacology 1986;25:799-802.
137. Grubb BP, Samoil D, Kosinski D, Wolfe D, Lorton M, Madu E. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med 1994;97:366-368.
138. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Beasley C. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharm 1999;19:9-14.
139. Skop BF, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the counter cold remedy, and vascular disease. Am J Emerg Med 1994;12:642-644.
140. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 2000;79:201-209.
141. 1D receptors mediate inhibition of sympathetic ganglionic transmission in anaesthetized cats. Br J Pharmacol 1995;116:1715-1717.
142. Csaba G, Sudar F. Localization of radioactively labeled serotonin in the nucleus of adrenal medulla cells. Acta Anat 1978;100:237-240.
143. Verhofstad AA, Jonsson G. Immunohistochemical and neurochemical evidence for the presence of serotonin in the adrenal medulla of the rat. Neurosci 1983;10:1443-1453.
144. Holzwarth MA, Sawetawan C, Brownfield MS. Serotonin immunoreactivity in the adrenal medulla: Distribution and response to pharmacological manipulation. Brain Res Bull 1984;13:299-308.
145. Brownfield MS, Poff BC, Holzwarth MA. Ultrastructural immunocytochemical co-localization of serotonin and PNMT in adrenal medullary vesicles. Histochemistry 1985;83:41-46.
146. Holzwarth MA, Brownfield MS. Serotonin coexists with epinephrine in rat adrenal medullary cells. Neuroendocrinology 1985;41:230-236.
147. Bacon SJ, Smith AD. Preganglionic sympathetic neurons innervating the rat adrenal medulla: Immunocytochemical evidence of synaptic input from nerve terminals containing substance P, GABA or 5-hydroxytryptamine. J Auton Nerv Syst 1988;24:97-122.
148. Alper RH. Evidence for central and peripheral serotonergic control of corticosterone secretion in the conscious rat. Neuroendocrinology 1990;51:255-260.
149. Sugimoto Y, Yamada J, Yoshikawa T, Nishikawa F, Noma T, Horisaka K. The involvement of serotonin in the catecholamine release from the adrenal medulla. Adv Exp Med Biol 1996;398:561-563.
150. Bagdy G, Calogero AE, Murph DL, Szemeredi K. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. Endocrinology 1989;125:2664-2669.